bioRxiv · 10.1101/2024.09.13.612358
Proof of Concept for High-Dose Cannabidiol Pretreatment to Antagonize Opioid Induced Persistent Apnea
Abstract
Using a mouse equivalent of FDA-approved cannabidiol (CBD) dosing, we found high dose CBD affects opioid induced persistent apnea (OIPA), the principal cause of opioid related fatalities. CBD pretreatment mitigated respiratory depression from fentanyl in awake mice and significantly delayed OIPA onset in anesthetized mice, effective as the opioid antagonist naloxone. The powerful effect of CBD pretreatment on OIPA suggests a novel therapeutic strategy to reduce fatal opioid overdose incidence.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Wiese, B. M., Bondarenko, E., Feldman, J. L.. 2024-09-14. Proof of Concept for High-Dose Cannabidiol Pretreatment to Antagonize Opioid Induced Persistent Apnea. https://doi.org/10.1101/2024.09.13.612358
Cite the original work for its findings. Save a collection to share your selection of sources.